| 摘要 |
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of structural formula (I), which possess the properties of HCV polymerase inhibitors. In formula,is specified in a group consisting of a single carbon-carbon bond and a double carbon-carbon bond; Rand Rare specified in hydrogen and methyl; Rrepresents hydrogen; Ris specified in a group consisting of hydrogen, hydroxy, C-Calkyl, C-Calkenyl, C-Calkynyl, C-Calkoxy, C-Calkenyloxy, C-Calkynyloxy and halo; L represents a bond, and Rrepresents a condensed 2-ring carbocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of R, R, R, R, R, Rand R; or L is specified in a group consisting of a bond, C?C, C(O)N(R), N(R)C(O), C-C-alkylene, C(H)O, OC(H), cyclopropyl-1,2-ene, C(H)N(R), N(R)C(H), C(O)CHand CHC(O), and Ris specified in a group consisting of C-C-carbocyclyk and 5-6-merous heterocyclyl, wherein each substitute is optionally substituted by one or more substitutes independently specified in a group consisting of R, R, R, R, R, R, R, Rand R; the R, R, R, R, R, R, R, R, Rand Rvalues are presented in the patent claim.EFFECT: invention refers to a pharmaceutical composition containing the above compounds, to using the compounds for producing a drug preparation for HCV RNA polymerase inhibition and hepatitis C treatment, and to a method for preparing the above compounds.21 cl, 46 dwg, 42 tbl, 140 ex |
